NLRP1: A Potential Drug Target for Cancer (G7182)

Target Name: NR2C2

NCBI ID: G7182

NR2C2

NLRP1: A Potential Drug Target for Cancer

NR2C2, short for Nucleotide Research Center 2, is a gene located on chromosome 16 that has been identified as a potential drug target for various diseases, including cancer. The gene is involved in the production of a protein known as NLRP1, which is a key regulator of the immune response and has been linked to a number of diseases, including cancer.

One of the reasons why NLRP1 is considered a potential drug target is because it has been shown to be over-expressed in a variety of cancer types, including breast, ovarian, and prostate cancer. Additionally, studies have suggested that NLRP1 may be involved in the development of resistance to cancer treatments, which could make it an attractive target for drugs that are currently used to treat these diseases.

Another potential mechanism by which NLRP1 may be involved in the development of cancer is its role in the regulation of cell death. NLRP1 has been shown to play a role in the production of a protein called BCL-2, which is a protein that helps to protect cells from programmed cell death. This is important because when cells are no longer needed, they can become cancerous and continue to divide and proliferate. By interfering with the production of BCL-2, NLRP1 may be able to promote cell death and reduce the risk of cancer.

Another potential mechanism by which NLRP1 may be involved in the development of cancer is its role in the regulation of cell signaling. NLRP1 has been shown to play a role in the production of a protein called TAS-40, which is involved in the regulation of cell signaling. This is important because signaling pathways are often involved in the development and progression of cancer, and interfering with these pathways could be a potential strategy for the development of cancer treatments.

In addition to its potential role in the development of cancer, NLRP1 is also considered a potential biomarker for cancer. This is because its expression has been shown to be often increased in the tissues of people with cancer, which could make it an attractive target for diagnostic tests. Additionally, the production of NLRP1 has been shown to be often increased in the blood of people with cancer, which could make it an attractive target for biomarker studies.

Overall, NLRP1 is a gene that has been identified as a potential drug target for various diseases, including cancer. Its role in the production of the immune response and its potential involvement in the regulation of cell death and signaling pathways make it an attractive target for the development of cancer treatments. Further research is needed to fully understand the role of NLRP1 in the development of cancer and to develop safe and effective treatments.

Protein Name: Nuclear Receptor Subfamily 2 Group C Member 2

Functions: Orphan nuclear receptor that can act as a repressor or activator of transcription. An important repressor of nuclear receptor signaling pathways such as retinoic acid receptor, retinoid X, vitamin D3 receptor, thyroid hormone receptor and estrogen receptor pathways. May regulate gene expression during the late phase of spermatogenesis. Together with NR2C1, forms the core of the DRED (direct repeat erythroid-definitive) complex that represses embryonic and fetal globin transcription including that of GATA1. Binds to hormone response elements (HREs) consisting of two 5'-AGGTCA-3' half site direct repeat consensus sequences. Plays a fundamental role in early embryonic development and embryonic stem cells. Required for normal spermatogenesis and cerebellum development. Appears to be important for neurodevelopmentally regulated behavior (By similarity). Activates transcriptional activity of LHCG. Antagonist of PPARA-mediated transactivation

The "NR2C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR2C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets